How much has Iambic Therapeutics raised?

Iambic Therapeutics has about $153 million disclosed based on public reporting. 2020: Seed/early — Undisclosed, led/backed by Reported venture investors. 2021: Series A — $53 million, led/backed by Lux Capital. 2023: Series B — $100 million, led/backed by Ascenta Capital and others (Valuation undisclosed).

Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.

The disclosed investor base includes Reported venture investors; Lux Capital; Ascenta Capital and others. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.

For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.

The latest public marker is Undisclosed. Valuation movement appears tied to progress in ai drug discovery, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.

No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.

Iambic Therapeutics has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.

The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.

The funding profile suggests budget exists for tools tied directly to ai drug discovery, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.

The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.